Article and Video CATEGORIES

Cancer Journey

Search By

ABOUT
Denise Brock

Denise has over 30 years of varying experience in the healthcare arena.  In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees.  She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.  

 

Lung Cancer Video Library - Spanish Language: Video #7 What is the best treatment for frail patients with advanced NSCLC?
¿Cuál es el mejor tratamiento para pacientes débiles con cáncer pulmonar de células no pequeñas en estado avanzado?
Author
Denise Brock
 

For our 7th video in the GRACE Spanish Lung Cancer Library, Antonio Calles, MD, Medical Oncologist, Thoracic Oncology Program, Hospital General Universitario, Gregorio Marraron, Madrid, Spain joined GRACE to discuss the best treatment for frail patients with advanced NSCLC.

 


 

TRANSCRIPTS - Spanish and English
 

¿Cuál es el mejor tratamiento para pacientes débiles con cáncer pulmonar de células no pequeñas en estado avanzado?

Desgraciadamente a veces cuando se diagnostica el cancer de pulmón, el paciente tiene mucha sintomatología derivado de ese tumor, esto es lo que nosotros nos referimos como “performance status” (PS) que es la situación clínica del tumor. Los pacientes que tienen un performance status de 3-4, es decir, que pasan la mayor parte de su día en la cama y no son capaces de autocuidado, se les aconseja el uso de tratamiento y es muy encarecido que reciban terapia paliativa de soporte, no necesariamente de hospicio, puede ser de manera ambulatoria.

Para los pacientes con mejor situación funcional de 0 a 1 están claras las recomendaciones.

La gran duda son los pacientes con un performance status de 2. En primer lugar, porque la definición de un performance status de 2 es ambigua y es difícil definir esta población. Hay PS 2 que realmente son PS 3 y hay PS 2 que realmente son PS 1. Por lo tanto, en la interpretación de los ensayos clínicos, hay que ser cauto porque no sabemos muy bien qué hacer con estos pacientes. En general, la decisión tiene que ser individualizada y tienen que tener gran peso las expectativas del paciente y de su familia. No podemos recomendar de manera sistemática el uso de quimioterapia o de cualquier otro tipo de quimioterapia a los pacientes con PS2 ya que en algunos pacientes el uso de quimioterapia se asocia a mayor toxicidad y en otra mejora la calidad de vida.

Normalmente se suele preferir los esquemas de monoterapia (un solo fármaco) sobre las combinaciones de platino por el riesgo de mayor toxicidad. Recientemente ha habido un estudio en el que comparaba la administración de carboplatino y pemetrexed sobre pemetrexed solo, demostrando un beneficio en supervivencia y control de la enfermedad con la combinación de carboplatino y pemetrexed. La decisión de tratar o no a un paciente con PS2 debe ser individualizada, no hay recomendaciones generales y se deben de basar fundamentalmente en las expectativas del paciente, la familia y las recomendaciones del médico oncólogo. En cualquier caso, todos estos pacientes deben recibir de una manera precoz un tratamiento paliativo de soporte.


 

Which is the best treatment for weak patients with non-small cell lung cancer in advanced stage?

Unfortunately, sometimes lung cancer is diagnosed in patients with many symptoms from the tumor; this is what we call performance status (PS) which is the clinical situation of the tumor. Patients with a performance status of 3-4, spend most of their day in bed and cannot take care of themselves. They are advised to have a treatment and palliative support therapy, not necessarily from a hospice, it could also be at home.

For patients with a performance status of 0-1 the recommendations are clear.

The big doubt is in patients with a performance status of 2. First of all, because the definition of PS 2 is not clear and it’s harder to define the specific population. There are PS 2 that are truly PS3 and there are also P2 that are PS1. In the interpretation of clinical trials, one has to be careful because we don’t know what to do with these patients. In general, the decision has to be individualized and the most important part are the expectations from the patient and family. We cannot recommend systematically the use of chemotherapy or any other treatment because the result is unknown, so in some patients it can cause toxicity but in others it could improve the quality of life.

 Usually the monotherapies are preferred over combinations with platinum because of the possible toxicity risk. Recently there has been a study where they compared carboplatin and pemetrexed over pemetrexed alone. The result showed an improved in survival and control of the disease using carboplatin and pemetrexed. The decision to treat or not a patient with PS2 is personalized, there are no general recommendations and it the decision has to be based on the patient’s expectative, the family and the oncologist. In any case, all these patients have to receive an early palliative support treatment.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
Imagine your body's defense system, the lymphatic system, suddenly turning against you. This is the reality for those facing lymphoma, a cancer of the immune system's crucial network. This article delves into the complexities of lymphoma, exploring its various forms, from the aggressive to the indolent, and examining the latest breakthroughs in treatment, including the groundbreaking POLARIX trial and cutting-edge therapies for relapsed cases. Whether you're a patient, a loved one, or simply curious about this complex disease, this comprehensive overview will provide valuable insights into the current state of lymphoma care and the promising future of research.
Image
Melanoma Video Library
Video
In these videos, Dr. Autumn Starnes gives an overview of melanoma's prevalence and risk factors. She also discusses the ABCDE method of self-screening for skin cancer, common misconceptions regarding people of color, and melanoma, and how a person can lower their risk of developing melanoma, among other relevant topics regarding melanoma.  To watch the complete playlist, click here. 
Image
Tumor Treating Fields 2023
Video
In this video, GRACE provides an overview of Tumor Treating Fields, a wearable device that may be used to treat mesothelioma and glioblastoma multiforme.  Video Transcript.

Recent Comments

JOIN THE CONVERSATION
Hi krivene,

 

Welcome to…
By JanineT GRACE … on
My dad was given Tarceva in…
By krivennneee on
Thanks for the video.
By HildaEberle on
Z, Don't apologize for…
By JanineT GRACE … on